1-9 of 9
Albert Assad
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh
Journal: Blood
Blood (2022) 140 (Supplement 1): 6117–6118.
https://doi.org/10.1182/blood-2022-164699
Published: 2022
Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood
Blood (2022) 140 (Supplement 1): 579–582.
https://doi.org/10.1182/blood-2022-160384
Published: 2022
Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood
Blood (2021) 138 (Supplement 1): 3647.
https://doi.org/10.1182/blood-2021-148668
Published: 2021
Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 353.
https://doi.org/10.1182/blood-2018-99-111338
Published: 2018
Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Sarah K. Tasian, MD, Albert Assad, MD, Deborah S Hunter, PhD, Yining Du, PhD, Mignon L. Loh, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 555.
https://doi.org/10.1182/blood-2018-99-110221
Published: 2018
Journal Articles

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Clinical Trials & Observations
Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Huiling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood
Blood (2017) 130 (15): 1768–1771.
https://doi.org/10.1182/blood-2017-02-765032
Published: 2017
Includes: Supplemental data
Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 714.
https://doi.org/10.1182/blood.V124.21.714.714
Published: 2014
Journal Articles

A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.

Luis H Camacho, MD, MPH, Robin Joyce, MD, Jennifer R Brown, MD, PhD, Asher Chanan-Khan, MD, Philip C. Amrein, MD, Albert Assad, MD, Marion Carrigan
Journal: Blood
Blood (2009) 114 (22): 3425.
https://doi.org/10.1182/blood.V114.22.3425.3425
Published: 2009
Journal Articles

Characterization of MDX-1401, a Human Anti-CD30 Antibody with Enhanced Effector Function, for Therapy of Malignant Lymphoma.

Pina M. Cardarelli, PhD., Cristina Loomis, PhD., Ben Preston, Amelia Black, PhD., David Passmore, PhD., Tseng-Hui Chen, PhD., Sharline Chen, Jie Liu, PhD., Michelle R Kuhne, PhD, Mohan Srinivasan, PhD., Albert Assad, MD, Alison Witte, Marco Coccia, PhD, Robert F. Graziano, PhD., David J. King, PhD.
Journal: Blood
Blood (2008) 112 (11): 1580.
https://doi.org/10.1182/blood.V112.11.1580.1580
Published: 2008